In light of the pandemic situation events until September 2021 are cancelled. We will inform customers directly when the events are rescheduled.    
COVID CANCELLED: Project Management in Human Resources,   Boston MA, Jan 6-8, 2021
COVID CANCELLED: InterDrone, The International Drone Conference,   Cambridge MA, Jan 11-13, 2021
COVID CANCELLED: Supplier Management for Medical Device Manufacturers,   Cambridge MA, Feb 2-4, 2021
COVID CANCELLED: US Immigration Compliance Strategies,   Boston MA, Feb 15-18, 2021
COVID CANCELLED: Project Management Training,   Boston MA, Mar 3-5, 2021
COVID CANCELLED: Internal Audit, Fraud Risk Assessment Workshop,   Boston MA, Mar 22-25, 2021
COVID CANCELLED: Agile / Scrum Training,   Boston MA, Apr 12-14, 2021
COVID CANCELLED: Validation, Verification and Transfer of Analytical Methods,   Boston MA, Apr 19-21, 2021
COVID CANCELLED: Computer System Validation - Reduce Costs and Avoid 483s,   Boston MA, May 10-12, 2021
COVID CANCELLED: SharePoint Technology Conference,   Boston MA, May 26-28, 2021
COVID CANCELLED: Employment Laws Certificate Program,   Boston MA, Jun 7-9, 2021
Following events are tentatively planned but may be rescheduled, based on CDC guidelines or attendee registration interest .    
TENTATIVE: 21 CFR Part 11 Compliance,   Boston MA, Sep 22-24, 2021
TENTATIVE: Quality Control Laboratory Compliance,   Boston MA, Oct 6-8, 2021
TENTATIVE: Analytical Instrument Qualification and System Validation,   Boston MA, Nov 15-17, 2021
TENTATIVE: FDA's New Import Program for 2021,   Boston MA, Dec 7-9, 2021

Boston Professional Events List

2nd Integrin-Targeted Drug Development Summit

Aug 31, 2022 - 08:30 AM - Sep 01, 04:00 PM
Hanson Wade
Hilton Boston Logan Airport
One Hotel Drive,

ZIP: 02128
Phone: +16174554188

Ticket Price: USD 2599.00 - USD 5696.00

Over the last 12 months, the industry has witnessed promising data and candidates entering the clinic. 7 Hills Pharma, Corbus Pharmaceuticals, Vincerx, and Morphic are paving the way to develop a safe, efficacious integrins-targeted drug to modify disease biology, which will be a game-changer for diseases such as oncology, autoimmune, and ophthalmology, with unmet medical needs.

In collaboration with leading integrin drug developers, including Genentech, 7 Hills Pharma, and Pfizer, the 2nd Integrin-Targeted Drug Development Summit is designed for industry leaders to unite and outline clinical strategies for success, including patient selection biomarkers and dosing.

Get your critical questions answered to supercharge your clinical programs, direct your drug pipelines and ensure you take lessons learned to successfully modulate integrins to improve treatment regimens in chronic, familiar, and rare diseases.

Join us for this 3-day summit to gain unparalleled insights and experience first-hand from integrin drug developers to accelerate your candidate into the clinic and develop a first-in-class treatment option by modifying underlying disease biology for our patients.

Tickets: https://go.evvnt.com/1173725-2?pid=1052
Brochure: https://go.evvnt.com/1173725-3?pid=1052

Drug Developer - Conference + Focus Day: USD 4796.00,
Drug Developer - Conference Only: USD 2999.00,
Academic and Start Ups - Conference + Focus Day: USD 4096.00,
Academic and Start Ups - Conference Only: USD 2599.00,
Service Provider - Conference + Focus Day: USD 5696.00,
Service Provider - Conference Only: USD 3599.00

Speaker Details

Bernhard Wehrle-Haller, Professor, Geneva University, Bruce Rogers, President, Morphic Therapeutics, Darren G. Woodside, Vice President of Research, Texas Heart Institute, Dermot Cox, Associate Professor Pharmacy and Biomolecular Sciences, Royal College of Surgeons, Ireland, Eric Lefevbre, Chief Medical Officer, Pliant Therapeutics, Evy LundgrenAkerlund, Chief Executive Officer, Xintela, Gregory Bix, Professor, Tulane University, Horst Kessler, Professor, Technical University Munich, Kevin Hart, Senior Principal Scientist, Pfizer, Per Norlén, Chief Executive Officer, Targinta, Peter Vanderslice, Co-Founder, 7 Hills Pharma, Riccardo Canevari, Chief Executive Officer, Radiopharm Theranostics, Scott Edwards, Chief Development Officer, OcuTerra, Scott Turner, Senior Vice President of Research, Pliant Therapeutics, Shaker Mousa, Professor and Chairman, Founder and Executive Vice President, Albany College, NanoPharmaceuticals, Stephen Nishimura, Professor, UCSF, Tangsheng Yi, Director, Inflammation/ Immunology, Gilead

Event Categories
Keywords: conference , pharmaceutical


Events Calendar

31 1 2 3 4 5 6
7 8 9 10 11 12 13
14 15 16 17 18 19 20
21 22 23 24 25 26 27
28 29 30 31 1 2 3


VIP Life Time Subscription to our Newsletters!